TUBERCULOSIS DRUG SCREENING NIH GUIDE, Volume 22, Number 33, September 17, 1993 RFP AVAILABLE: NIAID-DAIDS-94-24 P.T. Keywords: National Institute of Allergy and Infectious Diseases The Developmental Therapeutics Branch, Basic Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), has a requirement for the directed acquisition and evaluation of potential tuberculosis antimicrobials. The Request for Proposals (RFP) will contain two parts, with separate work statements for each part. Part A is the directed acquisition, distribution, and database component of this effort and Part B is the evaluation component. In Part A, the contractor will acquire compounds for screening against M. tuberculosis, maintain a computerized inventory for tracking of compounds, and coordinate and distribute compounds for evaluation (to the Contractor for Part B). Part B will require the evaluation and screening of compounds with potential as anti-tuberculosis agents. In Part B, the contractor will evaluate and screen compounds for antimicrobial activity against M. tuberculosis, evaluate the potential of selected compounds to inhibit the replication of intracellular M. tuberculosis, and develop and utilize new assays. Offerors may respond to more than one Part, but must submit separate Technical and Business proposals for each (under separate cover) to be considered. In order to avoid any potential conflict of interest by the acquisition contractor (Part A), a mandatory qualification criterion will be included to exclude pharmaceutical or chemical companies from participating as offerors. A pharmaceutical or chemical company is defined as an organization that sells drugs and/or chemicals to the general public for profit. An organization with any such commercial activity shall be excluded from competition. Also, approaches to Part B using a "virulent" form of M. tuberculosis must have a Bio-Safety Level 3 Facility at time of award to qualify. This announcement is a new solicitation and it is anticipated that there will be one award for each Part. The issuance of the RFA will be on or about September 17, 1993, and proposals will be due by COB on or about December 17, 1993. One cost-reimbursement, five-year contract is anticipated for each Part. INQUIRIES A short-form version of the RFA will be available, for informational purposes, which includes only the background information, the full Statement of Work, and Evaluation Criteria. There is sufficient information in this document to enable prospective offerors to determine if they have the expertise/capability to meet the Government's requirements. A full-text version will also be available, which includes all the necessary information, business forms, etc., in order to submit a proposal. There are a limited number of full-text versions available. Therefore, request the short form RFP first, then the full-text version only if you are going to submit a proposal. All requests must be in writing. Specify whether you are requesting the short-version or the full-text version of the RFP. FAX requests are acceptable, but it is preferred that requests be made in writing and two self-addressed mailing labels be provided. Requests for the RFA may be directed to: Mr. Ross Kelley Contract Management Branch National Institute of Allergy and Infectious Diseases Solar Building, Room 3C07 6003 Executive Boulevard Bethesda, MD 20892 Telephone: (301) 496-2509 FAX: (301) 402-0972 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |